We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
-12.76%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$277M
AUM Growth
-$51.6M
Cap. Flow
+$14.5M
Cap. Flow %
5.25%
Top 10 Hldgs %
42.56%
Holding
60
New
17
Increased
8
Reduced
13
Closed
11

Top Buys

Rank Stock Value
1
STXS icon
Stereotaxis
STXS
+$15.6M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$12.5M
3
TVRD
Tvardi Therapeutics
TVRD
+$10.2M
4
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$6.8M
5
QTRX icon
Quanterix
QTRX
+$5.16M

Top Sells

Rank Stock Value
1
LXRX icon
Lexicon Pharmaceuticals
LXRX
+$9.31M
2
CMRX
Chimerix, Inc.
CMRX
+$6.35M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$5.75M
4
ARVN icon
Arvinas
ARVN
+$4.84M
5
TGTX icon
TG Therapeutics
TGTX
+$3.75M

Sector Composition

Rank Sector Weight
1 Healthcare 99.16%
2 Miscellaneous 0.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SWAV
26
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$4.79M 1.73%
+160,000
New +$6.8M
ZYME icon
27
Zymeworks
ZYME
$2.07B
$4.22M 1.52%
170,000
– –
QTRX icon
28
Quanterix
QTRX
$125M
$4.06M 1.47%
+185,000
New +$5.16M
DNTH icon
29
Dianthus Therapeutics
DNTH
$6.24B
$3.95M 1.43%
24,063
-9,375
-28% -$1.78M
TGTX icon
30
TG Therapeutics
TGTX
$8.53B
$3.44M 1.24%
612,500
-537,500
-47% -$3.75M
RARX
31
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$3.35M 1.21%
141,800
+90,800
+178% +$2.69M
CRNX icon
32
Crinetics Pharmaceuticals
CRNX
$9B
$3.11M 1.13%
207,000
+171,000
+475% +$3.33M
THOR
33
DELISTED
Synthorx, Inc. Common Stock
THOR
$2.93M 1.06%
180,000
+22,400
+14% +$375K
NGNE icon
34
Neurogene
NGNE
$758M
$2.84M 1.03%
+49,750
New +$3.04M
FTSV
35
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$2.73M 0.99%
+425,000
New +$3.49M
NXTC icon
36
NextCure
NXTC
$27.6M
$2.62M 0.95%
+7,083
New +$2.3M
RDUS
37
DELISTED
Radius Health, Inc.
RDUS
$1.93M 0.7%
+75,000
New +$1.84M
APTO
38
DELISTED
Aptose Biosciences, Inc.
APTO
$1.5M 0.54%
+1,600
New +$1.82M
FLXN
39
DELISTED
Flexion Therapeutics, Inc.
FLXN
$1.44M 0.52%
+105,000
New +$1.25M
CCXI
40
DELISTED
ChemoCentryx, Inc.
CCXI
$1.36M 0.49%
+200,000
New +$1.5M
FOCL
41
EDAP TMS S.A.
FOCL
$199M
$1.35M 0.49%
+300,000
New +$1M
ITCI
42
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$1.27M 0.46%
+170,000
New +$1.63M
SBBP
43
DELISTED
Strongbridge Biopharma plc.
SBBP
$1.17M 0.42%
490,000
-650,000
-57% -$1.75M
CBAY
44
DELISTED
Cymabay Therapeutics
CBAY
$717K 0.26%
+140,000
New +$848K
VRML
45
DELISTED
Vermillion, Inc.
VRML
$661K 0.24%
1,265,000
-2,985,000
-70% -$1.98M
ASMB icon
46
Assembly Biosciences
ASMB
$709M
$492K 0.18%
+4,167
New +$630K
BLRX
47
BioLineRX
BLRX
$12.1M
$44K 0.02%
417
– –
TARA icon
48
Protara Therapeutics
TARA
$236M
$14K 0.01%
+1,350
New +$19.3K
AQST icon
49
Aquestive Therapeutics
AQST
$648M
– –
-590,000
Closed -$2.48M
ARVN icon
50
Arvinas
ARVN
$604M
– –
-220,000
Closed -$4.84M
1
2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q3 2019 Portfolio in Review

As of Q3 2019, Opaleye Management held 60 positions worth $277M, down 16% from $328M the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Opaleye Management deployed $14.5M of net new capital in Q3 2019, opening 17 new positions and adding to 8 existing holdings. Its largest new stake was Stereotaxis: 4,070,000 shares worth $14.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was TG Therapeutics, an estimated $3.75M trimmed.

  • Opaleye Management's largest Q3 2019 buy was Stereotaxis: 4,070,000 shares worth $14.3M.
  • Opaleye Management added most to Crinetics Pharmaceuticals in Q3 2019, an estimated $3.33M increase.
  • Opaleye Management's biggest Q3 2019 reduction was TG Therapeutics, cutting an estimated $3.75M.
  • Opaleye Management fully exited Lexicon Pharmaceuticals in Q3 2019, selling an estimated $9.31M.
  • Opaleye Management's ten largest holdings make up 43% of its $277M portfolio in Q3 2019.
  • Opaleye Management opened 17 new positions and closed 11 in Q3 2019.
  • Opaleye Management's portfolio value fell 16% quarter-over-quarter to $277M.

Based on Opaleye Management's 13F filing for Q3 2019, filed 14 Nov 2019.